Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials

Statistics in Medicine

Volumn 22, Issue 1, 2003, Pages 83-111

  Kafadar, Karen ^a   Prorok, Philip C ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bivariate gamma distribution; Cancer screening; Catch up time; Confidence interval coverage probability; Length bias; Logrank test; Sojourn time; Survival function

Indexed keywords

ARTICLE; BIOSTATISTICS; BREAST CANCER; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG CANCER; META ANALYSIS; METHODOLOGY; OVARY CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; SURVIVAL TIME;

ADULT; BREAST NEOPLASMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0037438438     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1331     Document Type: Article

References (23)

1. Prorok PC, Connor RJ, Baker SG. Statistical considerations in cancer screening programs. Urologic Clinics of North America 1990; 17:699-708.
2. Connor RJ, Prorok PC. Issues in the mortality analyses of randomized controlled trials of cancer screening. Controlled Clinical Trials 1994; 15:81-99.
3. Shapiro S, Venet W, Strax P, Venet L. Periodic Screening for Breast Cancer: The Health Insurance Plan Project and its Sequelae, 1963-1986. Johns Hopkins University Press: Baltimore, 1988.
4. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabar L, Larsson L. Breast cancer screening with mammography: overview of Swedish randomized trials. Lancet 1993; 341(8851):973-978.
5. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Cancer Screening Study: 1. Breast cancer detection and death rates among women aged. 40-49 years. Canadian Medical Association Journal 1992; 147:1459-1476.
6. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Cancer Screening Study: 2. Breast cancer detection and death rates among women aged 50-59 years. Canadian Medical Association Journal 1992; 147:1477-1488.
7. Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Cancer Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. Canadian Medical Association Journal 1992; 147:1477-1488.
8. Gohagan JK, Levin DL, Sullivan D, Prorok PC. The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Controlled Clinical Trials 2000; 21(6 Suppl):249S-406S.
9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. New England Journal of Medicine 1963; 328:1365-1371.
10. Aron JL, Prorok PC. An analysis of the mortality effect in a breast cancer screening study. International Journal of Epidemiology 1986; 15:36-43.
11. Etzioni R, Self SD. On the catch-up time method for analyzing cancer screening trials. Biometrics 1995; 51:31-43.
12. Kafadar K, Prorok PC. A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized trials. Statistics in Medicine 1994; 13:569-586.
13. Kafadar K, Prorok PC. Computer simulation experiments of randomized screening trials. Computational Statistics and Data Analysis 1996; 23:263-291.
14. Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR, Bernatz PE, Payne WS, Pairolero PC, Bergstalh EJ. Screening for lung cancer: a critique of the Mayo lung project. Cancer 1991; 67:1155-1164.
15. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms, Part I. Journal of Surgical Oncology 1995; 60:137-146.
16. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms, Part I. Journal of Surgical Oncology 1996; 61:68-83.
17. Kafadar K, Prorok PC, Smith PJ. An estimate of the variance of estimators for lead time and screening benefit in randomized cancer screening trials. Biometrical Journal 1998; 40:801-821.
18. Lawless JB. Statistical Models and Methods for Lifetime Data. Wiley: New York, 1982.
19. Zelen M, Feinleib M. On the theory of screening for chronic diseases. Biometrika 1969; 56:601-613.
20. Habbema JDF, Van Oortmarssen GJ, Van Putten DJ. An analysis of survival differences between clinically and screen-detected cancer patients. Statistics in Medicine 1983; 2:279-183.
21. Chen J, Prorok PC, Graff KM. An age dependent stochastic model of periodic screening: Length bias at a prevalence screen. Mathematical Biosciences 1983; 65:93-123.
22. Wichmann BA, Hill ID. Algorithm 183: An efficient and portable pseudo-random number generator. Applied Statistics 1982; 31:188-190.
23. Statistical Sciences Inc. S-Plus User's Manual, Version 3.4. Insightful: Seattle, Washington, 1996.